Last reviewed · How we verify
NK012
At a glance
| Generic name | NK012 |
|---|---|
| Sponsor | Nippon Kayaku Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of NK012 in Patients With Refractory Solid Tumors (PHASE1)
- A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer (PHASE2)
- Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer (PHASE1)
- Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (PHASE1)
- A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK012 CI brief — competitive landscape report
- NK012 updates RSS · CI watch RSS
- Nippon Kayaku Co., Ltd. portfolio CI